Orally administrable composition capable of providing enhanced bioavailability when ingested
US6312704A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jan 18, 2000 |
| Grant date | Nov 6, 2001 |
| Priority date | — |
| Expiry date | Jan 18, 2020 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61Q19/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Composition for pharmaceutical or cosmetic use, capable of providing enhanced bioavailability when ingested, comprising at least a pharmaceutical active ingredient, a lipophilic phase consisting of a mixture of fatty acid esters and glycerides, a surfactant (SA), and a cosurfactant (CoSA). The lipophilic phase consists of a mixture of C.sub.8 to C.sub.18 polyglycolized glycerides having hydrophilic-lipophilic balance (HLB) of less than 16, this lipophilic phase representing from 32 to 75% of the total weight of the composition. The surfactant (SA) is chosen from the group comprising saturated C.sub.8 -C.sub.10 polyglycolized glycerides and oleic esters of polyglycerol, this surfactant having an HLB of less than 16. The cosurfactant (CoSA) is chosen from the group comprising lauric esters of propylene glycol, oleic esters of polyglycerol and ethyl diglycol. The SA/CoSA ratio is between 0.5 and 6 and the hydrophilic phase of the final microemulsion is supplied after ingestion by the physiological fluid of the digestive milieu.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.